全文获取类型
收费全文 | 1689篇 |
免费 | 139篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 29篇 |
妇产科学 | 44篇 |
基础医学 | 260篇 |
口腔科学 | 99篇 |
临床医学 | 118篇 |
内科学 | 239篇 |
皮肤病学 | 21篇 |
神经病学 | 233篇 |
特种医学 | 94篇 |
外科学 | 283篇 |
综合类 | 9篇 |
预防医学 | 135篇 |
眼科学 | 12篇 |
药学 | 98篇 |
肿瘤学 | 142篇 |
出版年
2023年 | 16篇 |
2022年 | 8篇 |
2021年 | 37篇 |
2020年 | 29篇 |
2019年 | 50篇 |
2018年 | 44篇 |
2017年 | 38篇 |
2016年 | 42篇 |
2015年 | 39篇 |
2014年 | 54篇 |
2013年 | 65篇 |
2012年 | 86篇 |
2011年 | 126篇 |
2010年 | 46篇 |
2009年 | 43篇 |
2008年 | 88篇 |
2007年 | 79篇 |
2006年 | 78篇 |
2005年 | 80篇 |
2004年 | 75篇 |
2003年 | 57篇 |
2002年 | 63篇 |
2001年 | 27篇 |
2000年 | 26篇 |
1999年 | 34篇 |
1998年 | 21篇 |
1997年 | 21篇 |
1996年 | 12篇 |
1995年 | 13篇 |
1994年 | 20篇 |
1993年 | 13篇 |
1992年 | 30篇 |
1991年 | 27篇 |
1990年 | 49篇 |
1989年 | 35篇 |
1988年 | 25篇 |
1987年 | 39篇 |
1986年 | 30篇 |
1985年 | 24篇 |
1984年 | 11篇 |
1983年 | 20篇 |
1982年 | 12篇 |
1981年 | 20篇 |
1980年 | 12篇 |
1979年 | 17篇 |
1978年 | 8篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1974年 | 8篇 |
1973年 | 7篇 |
排序方式: 共有1833条查询结果,搜索用时 15 毫秒
21.
HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous population 总被引:3,自引:0,他引:3
A. Svejgaard B. K. Jakobsen P. Platz L. P. Ryder J. Nerup M. Christy K. Borch-Johnsen H.-H. Parving T. Deckert L. Mølsted-Pedersen C. Kühl K. Buschard A. Green 《Tissue antigens》1986,28(4):237-244
A total of 317 unrelated Danish patients with insulin-dependent diabetes mellitus (IDDM) have been HLA-DR typed and the antigen and phenotype frequencies compared with those in 1177 unrelated Danish controls. The strong positive associations with DR3 and 4 and the strong negative one with DR2 were confirmed, and the remaining antigens showed a hierarchy from weakly positive to strongly negative associations: DRw9, w8, 1, 5, w6, 7. The study population included various special groups of patients selected in order to study heterogeneity: very early (less than 5 years) and very late (greater than 40 years) onset IDDM, pregnancy-induced IDDM, IDDM nephropathy, and long-term (greater than 40 years) survivors without complications. When comparing these groups, the following minor differences were seen: the DR3,4 phenotype is significantly (p = .02) more frequent in IDDM with onset before age 20 (35%) than in other cases (24%), and in familial IDDM (48%) than in other cases (28%); the frequency of the DR4 antigen was significantly (p = .008) more frequent in long-term survivors (86%) than in other patients (69%), while it was significantly (p = .02) less frequent in IDDM nephropathy (63%) than in long-term survivors. However, apart from the age-at-onset heterogeneity, which was suspected a priori, these differences may be due to chance, and the main conclusion of this study is that the HLA-DR associations in IDDM are indeed extraordinarily homogeneous irrespective of the clinical characteristics at onset and course of the disease. 相似文献
22.
HLA-DP and bonemarrow transplantation: DP-incompatibility and severe acute graft versus host disease 总被引:6,自引:0,他引:6
N. Ødum P. Platz B. K. Jakobsen C. Munck Petersen N. Jacobsen J. Møller L. P. Ryder L. Lamm A. Svejgaard 《Tissue antigens》1987,30(5):213-216
Thirteen recipients of HLA-haploidentical, DR compatible bone marrow (BM) and the corresponding BM donors were HLA-DP typed using primed lymphocyte typing (PLT). Severe acute GVHD (greater than or equal to grade 2) developed within 3 months after BM-transplantation in all of eight recipients of DP incompatible BM, but in none of five recipients of DP-compatible BM. This difference was highly significant (p less than 0.001, Fisher's exact test). Moreover, severe acute GVHD was significantly increased in recipients of haploidentical, DR compatible, but DP incompatible BM as compared to severe acute GVHD in 88 recipients of HLA-identical BM (p less than 0.0001). In contrast, there was no difference in acute GVHD between recipients of haploidentical, DR and DP compatible BM and recipients of HLA-identical BM. The data presented here provide strong evidence for the first time that HLA-DP antigens play a role as transplantation antigens. 相似文献
23.
24.
Niels Ødum Niels Morling Johannes Friis Carsten Heilmann Jens J. Hyldig-Nielsen Bodil K. Jakobsen Freddy Karup Pedersen Per Platz Lars P. Ryder Arne Svejgaard 《Tissue antigens》1986,28(4):245-250
Thirty-six unrelated Danish patients with pauciarticular Juvenile Chronic Arthritis (PJCA) and 120 controls were typed for HLA-DPw1-w6 and the local specificity CDPHEI with bulk-expanded Primed Lymphocyte Typing (PLT) cells. The frequency of HLA-DPw2 was 52.8% in PJCA patients and 16.7% in controls (relative risk, RR = 4.5; P less than 0.001). The antigens HLA-Dw5 and/or Dw8 were present in 50% of the patients and in 21.3% of the controls (RR = 4.2; p less than 10(-3)). DPw2 was not associated (in linkage disequilibrium) with Dw5/w8 in patients or in controls, and the DP and D associations with PJCA were independent of each other. However, the combined presence of DPw2 and Dw5 and/or Dw8 gave a significantly higher risk of PJCA than each antigen alone indicating interaction of DP and DR gene products. PJCA is the first disease definitely found to be associated with a DP antigen. 相似文献
25.
26.
Preben Jakobsen Bente Søresen Lars Bastholt Mansoor Raza Mirza Susanne B. Gjedde Henning T. Mouridsen Carsten Rose 《Cancer chemotherapy and pharmacology》1994,35(1):45-52
A high-pressure liquid chromatographic method for determination of the bisdioxopiperazine derivative ADR-529 (ICRF-187), a compound proven effective in protection against anthracycline-induced cardiotoxicity, has been developed. The limit of quantitation was 5 ng/ml using a narrow-bore 5-m silica column and UV detection. The method was used for determination of pharmacokinetic profiles of ADR-529 after a 3-weekly i.v. administration of different doses of ADR-529 (600–1000 mg/m2) together with different doses of epirubicin (E, 60–100 mg/m2), fixed-dose cyclophosphamide (C, 600 mg/m2), fixed-dose 5-fluorouracil (F, 600 mg/m2), and daily administration of tamoxifen (T, 30 mg; CEF-T) in the treatment of patients with metastatic breast cancer. Pharmacokinetic parameters for epirubicin were also determined. The aim of the study was to determine (1) whether the pharmacokinetics of ADR-529 as part of a combination with CEF-T changes with increasing doses of ADR-529 and increasing doses of epirubicin and (2) whether the pharmacokinetics of epirubicin in the same combinations is altered with the administration of increasing doses of ADR-529. A total of 82 patients were included. A crossover study including 16 of the patients showed no significant difference in epirubicin pharmacokinetic parameters when epirubicin was given with or without concomitant administration of ADR-529. Apart from minor changes in the distributional half-lives, the pharmacokinetic parameters of epirubicin were not altered with increasing doses of ADR-529, nor were the pharmacokinetic parameters of ADR-529 itself. Escalating doses of epirubicin did not significantly alter the pharmacokinetic parameters of ADR-529 with the exception of a 30% increase in the terminal half-life and a decrease in total body clearance when the epirubicin dose was raised from 60 to 100 mg/m2. We conclude that concomitant administration of ADR-529 does not alter the distribution and elimination of epirubicin in doses suitable for preventing the anthracycline-induced cardiotoxicity. 相似文献
27.
Using the information obtained from the Collegiate Patient Management System a comparison of average numbers of procedures performed by third year dental students from 1983/84 to 1996/97 was made. The data were grouped in order to compare Group I (1983/1989) to Group II (1990/1997). Student's t-tests were performed to determine significant differences between the groups for the various procedures. The number of new patients in Group I was only 8.2 compared to Group II--7.9 and the total number of new and recall patients seen by students was Group I--33.5 compared to Group II--29.9. Students in Group I performed 19.3 one-surface restorations compared to 11.8 (p = .0001) in the later group and 9.5 two-surface restorations compared to 6.0 (p = .0003) for the 1990's group. Stainless steel crowns, pulpotomies, extractions and sealants were also compared. The total numbers of patients visits was 66.8 in GRP I compared to 49.6 (p;eq.0001) in GRP II. There has been a decrease in most student experiences in the undergraduate pediatric dental clinic in the past 15 years. 相似文献
28.
D. Blohm S. Kaalund B.W. Jakobsen 《Scandinavian journal of medicine & science in sports》1999,9(4):245-247
A case of an acute traction apophysitis, "little league elbow", in an adolescent badminton player is presented. After a period of intense badminton activity, the patient developed typical signs of inflammation related to his elbow. X-ray showed soft tissue calcifications and ultrasound showed intra-articular swelling and a possible apophysitis related to the elbow. After a period of immobilization followed by low activity he could return to normal sports activity. 相似文献
29.
Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer 总被引:2,自引:0,他引:2
Preben Jakobsen Eva Steiness Lars Bastholt Mads Dalmark Anders Lorenzen Dorthe Petersen Susanne B. Gjedde Erik Sandberg Carsten Rose Ole S. Nielsen Henning T. Mouridsen Anders Jakobsen 《Cancer chemotherapy and pharmacology》1991,28(1):63-68
Summary Pharmacokinetic analysis of epirubicin and its metabolites epirubicinol and 7-deoxy-13-dihydro-epirubicinol aglycone during the first and the fourth courses of treatment was performed in 78 patients with metastatic breast cancer. The patients were treated every 3 weeks with epirubicin given as 10-min i.v. infusions at four different dose levels: 40, 60, 90 and 135 mg/m2. In most cases (76 of 78 cases), plasma concentration-time curves fitted to a three-compartmental pharmacokinetic model. The terminal half-life of epirubicin was independent of dose and duration of treatment. Large interindividual differences were demonstrated (meant
1/2, 21.6±7.9 h; range, 10.6–69 h;n=110). In two subjects, extremely long half-lives and high serum bilirubin concentrations indicated impaired liver function. No correlation was found between the half-life and levels of liver alanine aminotransferase (ALAT) or serum creatinine. The metabolite epirubicinol appeared quickly after epirubicin administration and its half-lives were shorter than that of the parent compound (meant
1/2, 18.1±4.8 h; range, 8.2–38.4 h;n=105).Formation of the aglycone metabolite was delayed and the half-life of this metabolite was shorter than that of epirubicin (meant
1/2, 13±4.6 h; range, 2.7–29 h;n=104). The AUC of epirubicin and the total AUC (drug and metabolites) were linearly proportional to the dose, with the former value constituting two-thirds of the latter. A correlation was found between AUC and the plasma concentration of epirubicin at two time points (2 and 24 h after administration). The proposed model was AUC=9.44×c
2+62.5×c
24+157.7 (r=0.953).This work was supported by the Lundbeck Foundation, the Michaelsen Foundation and Farmitalia Carlo Erba Ltd. 相似文献
30.
D. Nielsen J. Eriksen C. Maare A. H. Jakobsen T. Skovsgaard 《British journal of cancer》1998,78(9):1175-1180
Fluctuation analysis experiments were performed to assess whether selection or induction determines expression of P-glycoprotein and resistance in the murine Ehrlich ascites tumour cell line (EHR2) after exposure to daunorubicin. Thirteen expanded populations of EHR2 cells were exposed to daunorubicin 7.5 x 10(-9) M or 10(-8) M for 2 weeks. Surviving clones were scored and propagated. Only clones exposed to daunorubicin 7.5 x 10(-9) M could be expanded for investigation. Drug resistance was assessed by the tetrazolium dye (MTT) cytotoxicity assay. Western blot was used for determination of P-glycoprotein. Compared with EHR2, the variant cells were 2.5- to 5.2-fold resistant to daunorubicin (mean 3.6-fold). P-glycoprotein was significantly increased in 11 of 25 clones (44%). Analysis of variance supported the hypothesis that spontaneous mutations conferred drug resistance in EHR2 cells exposed to daunorubicin 7.5 x 10(-9) M. At this level (5 log cell killing) of drug exposure, the mutation rate was estimated at 4.1 x 10(-6) per cell generation. In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10(-8) M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold), suggesting that in EHR2/0.8/R the mdr1 gene was activated by induction. In conclusion, our study demonstrates that P-glycoprotein expression and daunorubicin resistance are primarily acquired by selection of spontaneously arising mutants. However, under certain conditions the mdr1 gene may be activated by induction. 相似文献